You are viewing the site in preview mode

Skip to main content

Table 4 Predictive performance of CSF biomarkers for clinical progression among 139 samples

From: Alzheimer’s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans

Clinical variables Biomarkers
Aβ42 T-tau P-tau Aβ42/Aβ40 t-tau/Aβ42 p-tau/Aβ42
F, P value
CDR 4.139, 0.008 1.512, 0.215 1.127, 0.341 3.627, 0.015 2.831, 0.041 3.639, 0.015
CDR-SB 8.308, 0.0001 1.584, 0.197 1.011, 0.390 5.982, 0.001 4.472, 0.005 6.416, 0.0001
BDS-ADL 3.471, 0.018 1.634, 0.185 0.749, 0.525 2.975, 0.034 2.199, 0.092 3.095, 0.030
SBT 1.566, 0.201 1.500, 0.218 0.661, 0.578 2.002, 0.117 2.365, 0.074 1.720, 0.167
MMSE 3.434, 0.020 2.362, 0.076 1.358, 0.260 4.227, 0.007 4.277, 0.007 5.030, 0.003
Constructional praxis 2.921, 0.038 1.596, 0.195 0.335, 0.800 2.071, 0.109 2.244, 0.088 2.088, 0.107
Clock drawing 3.295, 0.024 3.482, 0.019 1.356, 0.261 4.751, 0.004 5.091, 0.003 5.034, 0.003
  1. Ten subjects with AD-like CSF signature (2, 1, and 7 at first, second, and third follow-ups, respectively) and 9 subjects with normal CSF signature (1, 4, and 4 at third, second, and first follow-ups, respectively) were lost to follow-up. Numbers in bold indicate the variables with significance under ANCOVA analysis
  2. CDR Clinical Dementia Rating scale, CDR-SB CDR-Sum of Boxes, BDS-ADL Blessed Dementia Scale-Activities of Daily Living, SBT Short Blessed Test, MMSE Mini-Mental State Examination